β-boomerang antimicrobial and antiendotoxic peptides: Lipidation and disulfide bond effects on activity and structure

Pharmaceuticals

Volumn 7, Issue 4, 2014, Pages 482-501

  Mohanram, Harini ^a   Bhattacharjya, Surajit ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Antibiotics; Antimicrobial peptides; Endotoxins; LPS; NMR; boomerang peptide

Indexed keywords

BETA BOOMERANG PEPTIDE; LIPOPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ACYLATION; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIENDOTOXIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; BACILLUS SUBTILIS; BACTERIAL STRAIN; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DISULFIDE BOND; DRUG ACTIVITY; DRUG CONFORMATION; DRUG POTENCY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; IN VITRO STUDY; ISOTHERMAL TITRATION CALORIMETRY; KLEBSIELLA PNEUMONIAE; LIGHT SCATTERING; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION; ZETA POTENTIAL;

EID: 84899130102     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph7040482     Document Type: Article

References (55)

1. Zasloff, M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415, 389-395.
2. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures and their modes of action. Trends. Biotechnol. 2011, 9, 464-472.
3. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.W.; Schneider, G. Designing antimicrobial peptides: Form follows function. Nat. Rev. Drug Discov. 2012, 11, 37-51.
4. Ganz, T.; Lehrer, R.I. Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 1998, 10, 41-44.
5. Shai, Y. From innate immunity to de-novo designed antimicrobial peptides. Curr. Pharm. Des. 2002, 8, 715-725.
6. Tossi, A.; Sandri, L.; Giangaspero, A. Amphipathic alpha helical antimicrobial peptides. Biopolym. (Pept. Sci.) 2000, 55, 4-30.
7. Boman, H.G. Peptide antibiotics and their role in innate immunity. Annu. Rev. Immunol. 1995, 13, 61-92.
8. Brown, K.L.; Hancock, R.E.W. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 2006, 18, 24-30.
9. Jenssen, H.; Powers, H.; Hancock, R.E.W. Peptide antimicrobial agents. Clin. Microbiol. Rev. 2006, 19, 491-511.
10. Hancock, R.E.W.; Lehrer, R.I. Cationic peptides: A new source of antibiotics. Trends. Biotechnol. 1998, 16, 82-88.
11. Aoki, W.; Ueda, M. Characterisation of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals 2013, 6, 1055-1081.
12. Brogden, N.K.; Brogden, K.A. Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int. J. Antimicrob. Agents 2011, 38, 217-225.
13. Epand, R.M.; Vogel, H.J. Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophys. Acta 1999, 1462, 11-28.
14. Bhunia, A.; Saravanan, R.; Mohanram, H.; Mangoni, M.L.; Bhattacharjya, S. NMR structures and interactions of temporin-1Tl and temporin-1Tb with lipopolysaccharide micelles. Mechanistic insights into outer membrane permeabilization and synergisitc activity. J. Biol. Chem. 2011, 286, 24394-24406.
15. Mohanram, H.; Bhattacharjya, S. Resurrecting inactive antimicrobial peptides from the lipopolysaccharide trap. Antimicrob. Agents Chemother. 2014, doi:10.1128/AAC.02321-13.
16. Barnickel, G.; Bradaczek, H.; Naumann, D.; Rietschel, E.T.; Giesbrecht, P.; Labischinski, H. High state of order of isolated bacterial lipopolysaccharide and its possible contribution to the permeation barrier property of the outer membrane. J. Bacteriol. 1985, 162, 9-13.
17. Allende, D.; McIntosh, T.J. Lipopolysaccharides in bacterial membranes act like cholesterol in eukaryotic plasma membranes in providing protection against melittin-induced bilayer lysis. Biochemistry 2003, 42, 1101-1108.
18. Mangoni, M.L.; Epand, R.F.; Rosenfeld, Y.; Peleg, A.; Barra, D.; Epand, R.M.; Shai, Y. Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J. Biol. Chem. 2008, 283, 22907-22917.
19. Marra, M.N.; Wilde, C.G.; Griffith, J.E.; Snable, J.L.; Scott, R.W. Bactericidal/permeability increasing protein has endotoxin neutralizing ability. J. Immunol. 1990, 144, 662-666.
20. Bhattacharjya, S. De novo Designed lipopolysaccharide binding peptides: structure based development of antiendotoxic and antimicrobial drugs. Curr. Med. Chem. 2010, 17, 3080-3093.
21. Raetz, C.R.; Whitfield, C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 2002, 71, 635-700.
22. Xu, J.; Kochanek, K.D.; Tejada-vera, B. Deaths: Preliminary data for 2007. National Vital Statistics Report, 2009, 58, 1-52.
23. David, S.A. Towards a rational development of anti-endotoxin agents: Novel approaches to sequestration of bacterial endotoxins with small molecules. J. Mol. Recognit. 2001, 14, 370-387.
24. Bowdish, D.M.E.; Hancock, R.E.W. Anti-endotoxin properties of cationic host defence peptides and proteins. J. Endotoxin. Res. 2005, 11, 230-236.
25. Lehrer, R.I.; Lichtenstein, A.K.; Ganz, T. Defensins: antimicrobial and cytotoxic peptides of mammlian cells. Annu. Rev. Immunol. 1993, 11, 105-128.
26. Kokryakov, V.N.; Harwig, S.S.L.; Panyutich, E.A.; Shevchenko, A.A.; Aleshina, G.M.; Shamova, O.V.; Korneva, H.A.; Lehrer, R.I. Protegrins: Leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS 1993, 327, 231-236.
27. Matsuzaki, K. Why and how are peptide-lipid interactions utilized for self defense? Magainins and tachyplesins as archetypes. Biochim. Biophys. Acta 1999, 1462, 1-10.
28. Harwig, S.S.L.; Waring, A.; Yang, H.J.; Cho, Y.; Tan, L.; Lehrer, R.I. Intramolecular disulfide bonds enhance the antimicrobial and lytic activities of protegrins at physiological sodium chloride concentrations. Eur. J. Biochem. 1996, 240, 352-357.
29. Mani, R.; Waring, A.J.; Lehrer, R.I.; Hong, M. Membrane disruptive abilities of beta hairpin antimicrobial peptides correlate with conformation and activity: A 31P and 1H NMR study. Biochim. Biophys. Acta 2005, 1716, 11-18.
30. Varkey, J.; Nagaraj, R. Antibacterial activity of human neutrophil defensin HNP-1 analogs without cysteines. Antimicrob. Agents Chemother. 2005, 49, 4561-4566.
31. Haney, E.F.; Vogel, H.J. NMR of antimicrobial peptides. Annu. Rep. NMR 2009, 65, 1-51.
32. Findlay, B.; Zhanel, G.G.; Schweizer, F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold. Antimicrob. Agents Chemother. 2010, 54, 4049-4058.
33. Andra, J.; Lohner, K.; Blondelle, S.E.; Jerala, R.; Moriyon, I.; Koch, M.H.; Garidel, P.; Brandenburg, K. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin derived peptide. Biochem. J. 2005, 385, 135-143.
34. Mangoni, M.L.; Shai, Y. Short native antimicrobial peptides and engineered ultrashort lipopeptides: Similarities and differences in cell specificities and modes of action. Cell. Mol. Life Sci. 2011, 68, 2267-2280.
35. Tsubery, H.; Ofek, I.; Cohen, S.; Fridkin, M. N-terminal modifications of Polymyxin B nonapeptide and their effect on antibacterial activity. Peptides 2001, 22, 1675-1681.
36. Farnaud, S.; Evans, R.W. Lactoferrin-a multifunctional protein with antimicrobial properties. Mol. Immunol. 2003, 40, 395-405.
37. Majerle, A.; Kidric, J.; Jerala, R. Enhancement of antibacterial and lipopolysacchride binding activities of a human lactoferrin peptide fragment by the addition of acyl chain. J. Antimicrob. Chemother. 2003, 51, 1159-1165.
38. Rosenfeld, Y.; Lev, N.; Shai, Y. Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 2010, 49, 853-861.
39. Lockwood, N.A.; Haseman, J.R.; Tirrell, M.V.; Mayo, K.H. Acylation of SC4 dodecapeptide increases bactericidal potency against Gram positive bacteria, including drug resistant strains. Biochem. J. 2004, 378, 93-103.
40. Etzerodt, T.; Henriksen, J.R.; Rasmussen, P.; Clausen, M.H.; Andresen, T.L. Selective acylation enhances membrane charge sensitivity of the antimicrobial peptide Mastoporan-X. Biophys. J. 2011, 100, 399-409.
41. Bhattacharjya, S.; Domadia, P.N.; Bhunia, A.; Malladi, S.; David, S.A. High-resolution solution structure of a designed peptide bound to lipopolysaccharide: Transferred nuclear Overhauser effects, micelle selectivity, and anti-endotoxic activity. Biochemistry 2007, 46, 5864-5874.
42. Bhunia, A.; Mohanram, H.; Domadia, P.N.; Torres, J.; Bhattacharjya, S. Designed beta-boomerang antiendotoxic and antimicrobial peptides: sturctures and activities in lipopolysaccharide. J. Bio. Chem. 2009, 284, 21991-22004.
43. Bhunia, A.; Geoklin, C.; Domadia, P.N.; Warshakoon, H.; Cromer, J.R.; David, S.A.; Bhattacharjya, S. Interactions of a designed peptide with lipopolysaccharide: Bound conformation and anti-endotoxic activity. Biochem. Biophys. Res. Commun. 2008, 369, 853-857.
44. Bhunia, A.; Mohanram, H.; Bhattacharjya, S. Lipopolysacchride bound structures of the active fragments of fowlicidin-1, a cathelicidin family of antimicrobial and antiendotoxic peptide from chicken, determined by transferred nuclear Overhauser effect spectroscopy. Biopolym. (Pept. Sci.) 2008, 92, 9-22.
45. Bhunia, A.; Domadia, P.N.; Bhattacharjya, S. Structural and thermodynamic analyses of the interaction between melittin and lipopolysaccharide. Biochim. Biophys. Acta 2007, 1768, 3282-3291.
46. Bhattacharjya, S.; Ramamoorthy, A. Multifunctional host defense peptides: Functional and mechanistic insights from NMR structures of potent antimicrobial peptides. FEBS J. 2009, 276, 6465-6473.
47. Guntert, P. Automated NMR protein structure calculation with CYANA. Meth. Mol. Biol. 2004, 278, 353-378.
48. Laskowski, R.A.; Rullmann, J.A.C.; MacAruthur, M.W.; Kaptein, R.; Thornton, J.M. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 1996, 8, 477-496.
49. Domingues, M.M.; Castanho, M.A.R.B.; Santos, N.C. RBPI21 promotes lipopolysaccharide aggregation and exerts its antimicrobial effects by (hemi)fusion of PG-containing membranes. PLoS One 2009, 4, 8385.
50. Srimal, S.; Surolia, N.; Balasubramanian, S.; Surolia, A. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipidA. Biochem. J. 1996, 315, 679-686.
51. Bhattacharjya, S.; David, S.A.; Mathan, V.I.; Balaram, P. Polymyxin B nonapeptide: Conformations in water and in the lipopolysaccharide bound state determined by two-dimensional NMR and molecular dynamics. Biopolymers 1997, 41, 251-265.
52. Bahar, A.A.; Ren, D. Antimicrobial peptides. Pharmaceuticals 2013, 6, 1543-1575.
53. Jiang, Z.; Vasil, A.I.; Vasil, M.L.; Hodges, R.S. "Specificity determinants" improve therapeutic indices of two antimicrobial peptides piscidin 1 and dermaseptin S4 against the gram-negative pathogens Acinetobacter baumannii and Pseudomonas aeruginosa. Pharmaceuticals 2014, 7, 366-391
54. Loose, C.; Jensen, K.; Rigoutsos, I.; Stephanopoulos, G. A linguistic model for the rational design of antimicrobial peptides. Nature 2006, 443, 867-869.
55. Wang, G. Database-Guided Discovery of Potent Peptides to Combat HIV-1 or Superbugs. Pharmaceuticals (Basel) 2013, 6, 728-758.